{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Biomea Fusion, Inc."},"Symbol":{"label":"Symbol","value":"BMEA"},"Address":{"label":"Address","value":"900 MIDDLEFIELD ROAD,4TH FLOOR, REDWOOD CITY, California, 94063, United States"},"Phone":{"label":"Phone","value":"+1 650 980-9099"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers."},"CompanyUrl":{"label":"Company Url","value":"https://www.biomeafusion.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Alex Cacovean","title":"Vice President-Clinical Development"},{"name":"Anthony Souza","title":"Head-Information Technology"},{"name":"Heow Tan","title":"Chief Technical & Quality Officer"},{"name":"Juan Pablo Frias","title":"Chief Medical Officer"},{"name":"Priyanka Mandava","title":"Vice President-Clinical Operations"},{"name":"Rainer M. Erdtmann","title":"President, Chief Operating Officer & Director"},{"name":"Thomas Butler","title":"Chairman & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}